NEW YORK (GenomeWeb News) – Caris Life Sciences today announced a distribution deal with IPS Genomix to provide patients access to Caris' tumor profiling service in certain Middle Eastern and African markets.
Caris' service, called Molecular Intelligence, uses multiple technologies, including immunohistochemistry, FISH/CISH, PCR, and next-generation sequencing, to provide actionable information to clinicians to develop a treatment plan.
This approach can shed more light on the genetic and protein alterations that drive tumor growth, Caris said, adding that such a method is most applicable with patients who have aggressive, rare, or refractory cancers where the standard-of-care guidelines have been exhausted, or where such guidelines are unclear, as well as where additional clinical trial options are needed.
"The Middle Eastern and African markets represent key areas of unmet medical need and commercial opportunity for Caris Life Sciences, and demonstrate a significant leap forward for our international global expansion plans," Ian Walker, VP - International at Caris Life Sciences, said in a statement. "Partnering with IPS Genomix offers us a large, diverse, and experienced team to help realize our goal to bring Caris Molecular Intelligence to patients and physicians across the globe."
Financial and other terms were not disclosed.